News & Events about Rafael Holdings Inc Class B.
Cranbury, N.J., June 16, 2022 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc.(Cornerstone or the Company), a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, today announced a publication on preclinical data supporting CPI-613 (devimistat) targeting ...
Cranbury, NJ, May 24, 2022 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc. (Cornerstone or the Company), a company focused on rare cancer therapeutics and formerly known as Rafael Pharmaceuticals, today announced that the European Medicines Agency (EMA) has granted orphan drug designation to ...
Company name change reflects mission to address significant unmet needs in rare cancer therapeutics, returning to company rootsCranbury, NJ, May 19, 2022 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (Rafael or the Company), a company focused on the development of rare cancer therapeutics, today ...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rafael Holdings, Inc. - RFL SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rafael Holdings, Inc. - RFL PR Newswire NEW YORK, March 26, 2022 NEW YORK, March 26, 2022 /PRNewswire...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rafael Holdings, Inc. - RFL SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rafael Holdings, Inc. - RFL PR Newswire NEW YORK, March 16, 2022 NEW YORK, March 16, 2022 /PRNewswire...